Fig. 3
Liposome-anchored anti-CD137 and IL-2-Fc rapidly accumulate in tumors. a, b Groups of C57Bl/6 mice (n = 3/group) were inoculated with 5 × 105 B16F10 tumor cells on day 0, and received i.v. injections of Alexa-568-labeled αCD137 and IL-2-Fc, Lipo-αCD137 + Lipo-IL2-Fc, IL-2-Fc alone, or Lipo-IL-2-Fc alone on day 10. One hour later, tumors were collected, and frozen sections were stained for CD31 and DAPI and imaged by confocal microscopy. Background-corrected fluorescence intensities of Alexa 568 in tumors were quantified by ImageJ. Scale bar, 100 µm. Blue: nuclei; green: CD31 staining; red: Alexa 568 labeled anti-CD137 or IL-2-Fc. **p < 0.001, ***p < 0.0001. Measurements shown are mean ± s.e.m.
